Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SY-5609 for the treatment of pancreatic cancer. SY-5609, a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, … [Read more…]
